BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18501497)

  • 1. Molecular cancer phenotype in normal prostate tissue.
    Schlomm T; Hellwinkel OJ; Buness A; Ruschhaupt M; Lübke AM; Chun FK; Simon R; Budäus L; Erbersdobler A; Graefen M; Huland H; Poustka A; Sültmann H
    Eur Urol; 2009 Apr; 55(4):885-90. PubMed ID: 18501497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA microarray analysis reveals metastasis-associated genes in rat prostate cancer cell lines.
    Reyes I; Tiwari R; Geliebter J; Reyes N
    Biomedica; 2007 Jun; 27(2):190-203. PubMed ID: 17713630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
    Walton TJ; Li G; McCulloch TA; Seth R; Powe DG; Bishop MC; Rees RC
    Prostate; 2009 Jun; 69(8):810-9. PubMed ID: 19189301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.
    Arencibia JM; Martín S; Pérez-Rodríguez FJ; Bonnin A
    Int J Oncol; 2009 Feb; 34(2):457-63. PubMed ID: 19148481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
    Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
    BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
    Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
    Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial comment on: Molecular cancer phenotype in normal prostate tissue.
    Füssel S
    Eur Urol; 2009 Apr; 55(4):891. PubMed ID: 18501498
    [No Abstract]   [Full Text] [Related]  

  • 11. P704P, P712P, and P775P: A genomic cluster of prostate-specific genes.
    Stolk JA; Jiang Y; Day CH; Klee JI; Zhang X; Dillon DC; Houghton RL; Harlan D; Reed SG; Xu J
    Prostate; 2004 Aug; 60(3):214-26. PubMed ID: 15176051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study.
    Erbersdobler A; Isbarn H; Steiner I; Schlomm T; Chun F; Mirlacher M; Sauter G
    Urology; 2009 Nov; 74(5):1169-73. PubMed ID: 19476978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen mRNA and protein levels in laser microdissected cells of human prostate measured by real-time reverse transcriptase-quantitative polymerase chain reaction and immuno-quantitative polymerase chain reaction.
    Pinzani P; Lind K; Malentacchi F; Nesi G; Salvianti F; Villari D; Kubista M; Pazzagli M; Orlando C
    Hum Pathol; 2008 Oct; 39(10):1474-82. PubMed ID: 18619642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
    Avgeris M; Koutalellis G; Fragoulis EG; Scorilas A
    Clin Biochem; 2008 Oct; 41(14-15):1140-9. PubMed ID: 18586020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked gene transcript level alterations occur early during radical prostatectomy.
    Schlomm T; Näkel E; Lübke A; Buness A; Chun FK; Steuber T; Graefen M; Simon R; Sauter G; Poustka A; Huland H; Erbersdobler A; Sültmann H; Hellwinkel OJ
    Eur Urol; 2008 Feb; 53(2):333-44. PubMed ID: 17448597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of circulating prostate cancer cells: a challenge to the clinical implementation of molecular biology (review).
    Schamhart DH; Maiazza R; Kurth KH
    Int J Oncol; 2005 Mar; 26(3):565-77. PubMed ID: 15703810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
    Schröder FH; Roobol MJ
    Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.